Anogenital human papillomavirus (HPV) is a common sexually transmitted infection and is associated with cutaneous manifestations varying from inapparent infections to genital warts, condylomata accuminata and different types of anogenital cancers such as anal, vulva or cervix carcinoma. HPVs are strictly epitheliotropic, preferentially targeting squamous epithelial cells. There are at least 90 genotypes including HPV6 and HPV11, which are found in 70-100% of the condylomata accuminata. The latter ones are referred to as benign or 'low-risk HPV types', whereas other genotypes, particularly HPV16 and HPV18, are termed 'high-risk HPV types' because of their oncogenic potential. 1 The recombinant human keratinocyte growth factor (KGF) Palifermin is a member of the fibroblast growth factor family and promotes proliferation and differentiation of several epithelial tissues such as transitional urothelial cells, hepatocytes, type II pneumocytes, gastrointestinal epithelial cells and in particular epidermal cells via binding to the human KGF receptor. 2, 3 Palifermin is currently used for prophylaxis of oral mucositis following high-dose chemo-and/or radiotherapy and autologous blood SCT. 4 We describe here the first case of a reactivation of anogenital HPV infection following the use of Palifermin.
In September 2007, a 32-year-old man presented with high paraplegia caused by intraspinal tumor growth associated with cervical lympadenopathy. Following hemilaminectomy and tumor resection the diagnosis of a diffuse large cell B-cell lymphoma stage IV was made. At the same time, HIV infection consistent with a stage of AIDS (Center of Disease Control category C2) was diagnosed. As a result, highly active antiretroviral therapy (HAART) with emtricitabine, tenofovir and nevirapine was commenced. CR of the non-Hodgkin lymphoma was achieved following six cycles of the R-CHOP regime (R: rituximab; CHOP: CY, doxorubicin, VCR, prednisone). Within 6 months following the last cycle of R-CHOP, the patient suffered from a relapse. He developed cervical lymphadenopathy and a lymphoma lesion at the left trigeminus nerve. Lymphatic tissue was also infiltrating the left orbit affecting the optic nerve. Salvage chemotherapy consisted of two cycles of high-dose MTX, ifosfamide followed by one cycle of high-dose cytarabine, thiotepa. Each systemic chemotherapy was accompanied by the administration of intrathecal liposomal cytarabine. PBSC were collected during pegylated-filgrastim-supported hematological reconstitution following the first cycle MTX/ifosfamide. The salvage regimen was effective and resulted in a second CR. High-dose chemotherapy and PBSC transplantation was envisaged as consolidation therapy. Therefore, three doses of Palifermin (4.2 mg per day) were administered i.v. on 3 consecutive days before high-dose conditioning therapy was initiated. As the start of high-dose therapy had to be postponed for 1 week because of a dental infection, a fourth dose of Palifermin was given 4 days after the last day of the preceding Palifermin administration. As a result of the first three doses the patient already sensed perianal pain, pruritus and paresthesia caused by extensive growth of perianal condyloma also affecting the anal canal (Figure 1 ), which the patient had developed in 1998. At that time all lesions had disappeared completely following laser treatment. The perianal symptoms were substantially aggravated shortly after the fourth infusion of Palifermin. High-dose chemotherapy consisting of carmustine, thiotepa and etoposide was given whereas local treatment of condylomata by laser dissection or imiquimod was deferred to the time after hematological reconstitution.
Anogenital HPV infections are sexually transmitted diseases with a high prevalence of coinfection with HIV. 1, 5 After the infection, the virus remains in the basal cells of the anogenital epithelium. Within the basal cell layer, HPV DNA can persist inapparently for many years in the absence of clinical manifestations. However, once the basal cells proliferate and differentiate, the HP virus replicates. 5 The human KGF Palifermin stimulates in particular the proliferation and growth of basal cells of several epithelial tissues including the gastrointestinal mucosa and epidermis. 2, 3 As a result of its stimulatory activity and antiapoptotic properties the epidermis thickens providing protection against cytotoxic drugs, in particular in the setting of high-dose chemotherapy and blood SCT. 4, 6 To the best of our knowledge there are no reports in the literature describing an association between the use of Palifermin and reactivation of anogenital HPV infection. As HPV16 is the most frequent HPV type found in homosexual HIV-positive men 7 and KGF can stimulate the growth of HPV16 DNA-containing immortalized human cervical epithelial cells, 8 a stimulating influence of KGF on the growth of HPV-bearing epithelial tissues is very likely.
As HIV coinfection is associated with persistence and reactivation of HPV infection, a modulating effect of the HIV infection on the HPV reactivation is conceivable, but unlikely, because CD4 þ cell count was 425/ml and there was no evidence of HIV RNA in blood. 1, 5, 7, 9 In addition, HAART was interrupted just 2 days before the first administration of Palifermin with regard to the risk of drug interactions and HAART-induced graft failure.
As the time of HPV reactivation sharply coincides with the administration of the epitheliotropic growth factor KGF, we assume a causative role of this factor for the recurrence of anogenital condylomata. This serious and extremely painful side effect of Palifermin should be taken into account especially in patients with a history of HPV infection in the past.
